Gunther Tulip Vena Cava Filter

FDA-Cleared Indications

• Prevention of pulmonary embolism by trapping embolic material in the inferior vena cava.
• Use in patients at risk for pulmonary embolism, including patients with venous thromboembolism.
• Use when anticoagulation is contraindicated, ineffective, or cannot be used.
• The filter may be used temporarily or left in place permanently when clinically indicated.

Clinical Applications

• Placement in the inferior vena cava for patients with deep vein thrombosis who are at risk for pulmonary embolism.
• Pulmonary embolism protection when anticoagulant therapy is contraindicated.
• Pulmonary embolism protection when anticoagulation is ineffective or cannot be tolerated.
• Temporary protection during a period of elevated thromboembolic risk, with retrieval considered when protection is no longer needed.
• Permanent filtration when ongoing pulmonary embolism risk or clinical circumstances support leaving the filter in place.

Reported off-label uses

• Prophylactic placement in selected trauma or surgical patients without confirmed venous thromboembolism but considered to have a high risk of pulmonary embolism.
• Use in selected patients with recurrent pulmonary embolism despite therapeutic anticoagulation.
• Placement in an anatomical location other than the standard infrarenal inferior vena cava in selected complex cases.

Off-label use: these uses are reported in practice or the literature but are not part of the FDA-cleared indications. Physicians may use a cleared device off-label based on their medical judgment; the manufacturer may not promote off-label uses.

Practical Considerations

• The device is delivered through a catheter, commonly through the internal jugular or femoral vein, and positioned in the inferior vena cava using fluoroscopic imaging.
• The filter is retrievable, but retrieval may become more difficult as dwell time increases or if the filter tilts, becomes embedded, or develops clot; patients need follow-up for retrieval planning.
• Available filter and delivery-system sizes, venous access requirements, and anatomical suitability must be confirmed in the current manufacturer instructions for use.
• MRI conditions and permitted scan parameters should be verified in the current device labeling before imaging. Do not assume that a filter is unrestricted for MRI.
• Potential complications include access-site bleeding, filter migration, tilt, fracture, penetration of the vena cava wall, filter thrombosis, and recurrent or new deep vein thrombosis.